Detalhe da pesquisa
1.
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.
N Engl J Med
; 380(8): 741-751, 2019 02 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-30786188
2.
Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics.
Cancer
; 123(19): 3843-3854, 2017 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28558150
3.
Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers.
Bioconjug Chem
; 26(5): 919-31, 2015 May 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-25915780
4.
Improving the therapeutic index in cancer therapy by using antibody-drug conjugates designed with a moderately cytotoxic drug.
Mol Pharm
; 12(6): 1836-47, 2015 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-25402018
5.
Anti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma.
Haematologica
; 99(11): 1738-45, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-25150258
6.
Predictive patient-specific dosimetry and individualized dosing of pretargeted radioimmunotherapy in patients with advanced colorectal cancer.
Eur J Nucl Med Mol Imaging
; 41(8): 1593-602, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-24643780
7.
Al(18) F labeling of peptides and proteins.
J Labelled Comp Radiopharm
; 57(4): 219-23, 2014 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-24408125
8.
Sacituzumab govitecan plus platinum-based chemotherapy mediates significant antitumor effects in triple-negative breast, urinary bladder, and small-cell lung carcinomas.
Oncotarget
; 15: 144-158, 2024 Feb 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38386805
9.
Pretargeted immuno-PET and radioimmunotherapy of prostate cancer with an anti-TROP-2 x anti-HSG bispecific antibody.
Eur J Nucl Med Mol Imaging
; 40(9): 1377-83, 2013 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-23674207
10.
New lyophilized kit for rapid radiofluorination of peptides.
Bioconjug Chem
; 23(3): 538-47, 2012 Mar 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-22273147
11.
Pretargeting: taking an alternate route for localizing radionuclides.
Tumour Biol
; 33(3): 591-600, 2012 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-22396041
12.
Optimized labeling of NOTA-conjugated octreotide with F-18.
Tumour Biol
; 33(2): 427-34, 2012 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-22009690
13.
Signal amplification in molecular imaging by pretargeting a multivalent, bispecific antibody.
Nat Med
; 11(11): 1250-5, 2005 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-16258537
14.
High-yielding aqueous 18F-labeling of peptides via Al18F chelation.
Bioconjug Chem
; 22(9): 1793-803, 2011 Sep 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-21805975
15.
A re-examination of radioimmunotherapy in the treatment of non-Hodgkin lymphoma: prospects for dual-targeted antibody/radioantibody therapy.
Blood
; 113(17): 3891-5, 2009 Apr 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-19182204
16.
Anti-CEA Pretargeted Immuno-PET Shows Higher Sensitivity Than DOPA PET/CT in Detecting Relapsing Metastatic Medullary Thyroid Carcinoma: Post Hoc Analysis of the iPET-MTC Study.
J Nucl Med
; 62(9): 1221-1227, 2021 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33547213
17.
Improved 18F labeling of peptides with a fluoride-aluminum-chelate complex.
Bioconjug Chem
; 21(7): 1331-40, 2010 Jul 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-20540570
18.
Sacituzumab govitecan, a novel, third-generation, antibody-drug conjugate (ADC) for cancer therapy.
Expert Opin Biol Ther
; 20(8): 871-885, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32301634
19.
Correction: Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC).
Oncotarget
; 11(10): 942, 2020 Mar 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32206190
20.
Predictive biomarkers for sacituzumab govitecan efficacy in Trop-2-expressing triple-negative breast cancer.
Oncotarget
; 11(43): 3849-3862, 2020 Oct 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-33196706